Literature DB >> 9811684

Efficient, repeated adenovirus-mediated gene transfer in mice lacking both tumor necrosis factor alpha and lymphotoxin alpha.

K Benihoud1, I Saggio, P Opolon, B Salone, F Amiot, E Connault, C Chianale, F Dautry, P Yeh, M Perricaudet.   

Abstract

The efficiency of adenovirus-mediated gene transfer is now well established. However, the cellular and the humoral immune responses triggered by vector injection lead to the rapid elimination of the transduced cells and preclude any efficient readministration. The present investigation focuses on the role of tumor necrosis factor alpha (TNF-alpha), a proinflammatory cytokine, and the related cytokine lymphotoxin alpha (LTalpha), in mounting an immune reaction against recombinant adenovirus vectors. After gene transfer in the liver, mice genetically deficient for both cytokines (TNF-alpha/LTalpha-/-), in comparison with normal mice, presented a weak acute-phase inflammatory reaction, a reduction in cellular infiltrates in the liver, and a severely impaired T-cell proliferative response to both Adenoviral and transgene product antigens. Moreover, we observed a strong reduction in the humoral response to the vector and the transgene product, with a drastic reduction of anti-adenovirus immunoglobulin A and G antibody isotypes. In addition, the reduction in antibody response observed in TNF-alpha/LTalpha-/- and TNF-alpha/LTalpha+/- mice versus TNF-alpha/LTalpha+/+ mice links antibody levels to TNF-alpha/LTalpha gene dosage. Due to the absence of neutralizing antibodies, the TNF-alpha/LTalpha knockout mice successfully express a second gene transduced by a second vector injection. The discovery of the pivotal role played by TNF-alpha in controlling the antibody response against adenovirus will allow more efficient adenovirus-based strategies for gene therapy to be proposed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811684      PMCID: PMC110450     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  Expression of human alpha 1-antitrypsin using a recombinant adenovirus vector.

Authors:  P Gilardi; M Courtney; A Pavirani; M Perricaudet
Journal:  FEBS Lett       Date:  1990-07-02       Impact factor: 4.124

2.  Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells.

Authors:  A E Tollefson; T W Hermiston; D L Lichtenstein; C F Colle; R A Tripp; T Dimitrov; K Toth; C E Wells; P C Doherty; W S Wold
Journal:  Nature       Date:  1998-04-16       Impact factor: 49.962

3.  Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice.

Authors:  H F Starnes; M K Pearce; A Tewari; J H Yim; J C Zou; J S Abrams
Journal:  J Immunol       Date:  1990-12-15       Impact factor: 5.422

4.  A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia.

Authors:  H S Ginsberg; L L Moldawer; P B Sehgal; M Redington; P L Kilian; R M Chanock; G A Prince
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

5.  Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection.

Authors:  B Thimmappaya; C Weinberger; R J Schneider; T Shenk
Journal:  Cell       Date:  1982-12       Impact factor: 41.582

6.  Role of early region 3 (E3) in pathogenesis of adenovirus disease.

Authors:  H S Ginsberg; U Lundholm-Beauchamp; R L Horswood; B Pernis; W S Wold; R M Chanock; G A Prince
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

7.  A modified double antibody sandwich enzyme-linked immunosorbent assay for measurement of alpha-1-antitrypsin in biologic fluids.

Authors:  J P Michalski; C C McCombs; S Sheth; M McCarthy; R deShazo
Journal:  J Immunol Methods       Date:  1985-10-24       Impact factor: 2.303

8.  Enhancement of in vivo immune response by tumor necrosis factor.

Authors:  P Ghiara; D Boraschi; L Nencioni; P Ghezzi; A Tagliabue
Journal:  J Immunol       Date:  1987-12-01       Impact factor: 5.422

9.  Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface.

Authors:  J L Browning; A Ngam-ek; P Lawton; J DeMarinis; R Tizard; E P Chow; C Hession; B O'Brine-Greco; S F Foley; C F Ware
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

10.  Interaction of recombinant IL-1 and recombinant tumor necrosis factor in the induction of mouse acute phase proteins.

Authors:  R F Mortensen; J Shapiro; B F Lin; S Douches; R Neta
Journal:  J Immunol       Date:  1988-04-01       Impact factor: 5.422

View more
  10 in total

1.  Adenoviral and adeno-associated viral transfer of genes to the peripheral nervous system.

Authors:  M Glatzel; E Flechsig; B Navarro; M A Klein; J C Paterna; H Büeler; A Aguzzi
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

Review 2.  Innate immunity to adenovirus: lessons from mice.

Authors:  Svetlana Atasheva; Jia Yao; Dmitry M Shayakhmetov
Journal:  FEBS Lett       Date:  2019-12-08       Impact factor: 4.124

Review 3.  Th17 cells and mucosal host defense.

Authors:  Shean J Aujla; Patricia J Dubin; Jay K Kolls
Journal:  Semin Immunol       Date:  2007-11-28       Impact factor: 11.130

4.  Cell targeting in anti-cancer gene therapy.

Authors:  Mohd Azmi Mohd Lila; John Shia Kwong Siew; Hayati Zakaria; Suria Mohd Saad; Lim Shen Ni; Jafri Malin Abdullah
Journal:  Malays J Med Sci       Date:  2004-01

5.  TNF-alpha -dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection.

Authors:  J M Trevejo; M W Marino; N Philpott; R Josien; E C Richards; K B Elkon; E Falck-Pedersen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

6.  Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver.

Authors:  Huang-Ge Zhang; Jinfu Xie; Liang Xu; Pingar Yang; Xin Xu; Sheher Sun; Yongming Wang; David T Curiel; Hui-Chen Hsu; John D Mountz
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

7.  Multiple treatment cycles of liposome-encapsulated adenoviral RIP-TK gene therapy effectively ablate human pancreatic cancer cells in SCID mice.

Authors:  Shi-He Liu; Nancy Smyth-Templeton; Alan R Davis; Elizabeth A Davis; Nikiforos Ballian; Min Li; Hao Liu; William Fisher; F Charles Brunicardi
Journal:  Surgery       Date:  2011-02-05       Impact factor: 3.982

Review 8.  Gene therapy for dyslipidemia: clinical prospects.

Authors:  D J Rader; U J Tietge
Journal:  Curr Atheroscler Rep       Date:  1999-07       Impact factor: 5.113

9.  Dissection of antiviral and immune regulatory functions of tumor necrosis factor receptors in a chronic lymphocytic choriomeningitis virus infection.

Authors:  M Suresh; Xiaoyan Gao; Christopher Fischer; Nicole E Miller; Kavita Tewari
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  Cationic liposome conjugation to recombinant adenoviral vector reduces viral antigenicity.

Authors:  A Natsume; M Mizuno; Y Ryuke; J Yoshida
Journal:  Jpn J Cancer Res       Date:  2000-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.